Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifaximin + fecal microbiota transplantation
- Development stage
- Unknown
- Lead developer
- Zhongshan Hospital, Fudan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Enteral
01
Overview
This combination therapy involves the sequential administration of rifaximin, a non-absorbable antibiotic, followed by fecal microbiota transplantation (FMT) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Rifaximin acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis and reducing the overall bacterial load or specific dysbiotic strains in the gastrointestinal tract. Following this decontamination phase, FMT is performed to introduce a diverse community of healthy commensal microorganisms from a donor, aiming to restore a balanced gut microbiome and alleviate symptoms such as abdominal pain and diarrhea. This specific regimen is being evaluated by Shanghai Zhongshan Hospital in clinical trials.
- Other names
- Rifaximin followed by FMTRifaximin combined with Fecal Microbiota Transplantation
02
Targets
rpoB (DNA-directed RNA polymerase subunit beta)
Beyond the preview
Go deeper on rifaximin + fecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifaximin + fecal microbiota transplantation.